COMPOUND

Compounds / GLP-1 agonists

Mazdutide

Mazdutide (IBI362; dual GLP-1 / glucagon receptor agonist)

GLP-1 agonists SubQ Approved outside the US

Innovent Biologics (China) / Eli Lilly licensed dual GLP-1 + glucagon receptor agonist. NMPA-approved June 2025 (chronic weight management) and September 2025 (T2D glycemic control), the first non-Lilly/Novo dual agonist on any major market and the world's first dual GCG/GLP-1 receptor agonist approved for diabetes. Innovent code: IBI362. Lilly licensed rights for development outside China. NOT FDA-approved as of 2026-05.

At a glance

Half-life
~7 days Once-weekly SubQ dosing: t½ ~7 days, similar to semaglutide and tirzepatide. ~60% bioavailability SC; Tmax ~48h.
Routes
SubQ
Evidence base
3 studies 3 human

Mechanism

Mazdutide simultaneously agonizes GLP-1R and glucagon receptor. GLP-1 component drives insulin secretion, gastric emptying delay, satiety (same as semaglutide). Glucagon component increases energy expenditure (thermogenesis), hepatic fat oxidation, and provides modest hyperglycemic pressure offset by the GLP-1 component. Distinct from tirzepatide (GLP-1 + GIP, where GIP improves insulin sensitivity differently) and from retatrutide (GLP-1 + GIP + glucagon triple agonist). The glucagon component is hypothesized to drive larger weight loss via increased energy expenditure beyond what semaglutide alone achieves. Phase 3 T2D efficacy trial; superior glycemic control vs dulaglutide; phase 1b safety of higher doses established.

Dosing

Any amounts shown here are reported from published studies only. 3 of 3 catalogued studies involved human subjects. COMPOUND does not publish its own dosing guidance.

Where a study reports an amount, it appears in that study's entry below, attributed to the source.

Published evidence

  1. Human RCT 2025

    DREAMS-1 Phase 3 trial of mazdutide in Chinese T2D adults

    DREAMS-1 trial group Nature

    Mazdutide met primary endpoint and all key secondary endpoints in Chinese T2D adults vs placebo. Significant HbA1c reduction and weight loss.

  2. Human RCT 2025

    DREAMS-2 Phase 3 trial of mazdutide vs dulaglutide in Chinese T2D

    DREAMS-2 trial group Nature

    Mazdutide superior to dulaglutide for HbA1c reduction, weight loss, and cardiometabolic markers in head-to-head trial.

  3. Human RCT 2023

    Safety and efficacy of mazdutide 9 mg and 10 mg in Chinese adults with overweight or obesity: phase 1b

    Ji L, et al. Diabetes Obes Metab

    Phase 1b multiple-ascending-dose study established safety and tolerability of higher mazdutide doses (9-10 mg); supported phase 3 dosing.

    PMID 36247927

Reported side effects

Nausea
Very common Mild · Class effect; 30-50% in titration phase. DREAMS trials.
Vomiting
Common Moderate · 10-20%; manageable with slower titration. DREAMS trials.
Diarrhea
Common Mild · 10-20%. DREAMS trials.
Decreased appetite
Very common Mild · Mechanism of action; intended.
Increased heart rate
Common Mild · Mild HR increase 3-5 bpm; class effect.
Hypoglycemia (combined with insulin/sulfonylurea)
Occasional Moderate · Combination care needed.

Interactions

  • Insulin Caution

    GLP-1 component increases insulin secretion; combined with exogenous insulin → hypoglycemia risk.

  • Semaglutide (SC) Contraindicated

    Both are GLP-1 agonists; combined use is duplicative GLP-1 stimulation.

  • Semaglutide (Oral) Contraindicated

    Both are GLP-1 agonists; combined use is duplicative GLP-1 stimulation.

  • Tirzepatide Contraindicated

    Overlapping GLP-1 receptor activity; redundant.

  • Retatrutide Contraindicated

    Overlapping GLP-1 + glucagon receptor activity; redundant.

Reconstitution and storage

Pre-filled pen expected (Innovent format). No user reconstitution.

Refrigerated 2-8°C; class-typical pen storage.

Open the reconstitution calculator for Mazdutide